Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 36 | 2024 | 772 | 12.190 |
Why?
|
| Anti-HIV Agents | 14 | 2024 | 149 | 6.830 |
Why?
|
| Pre-Exposure Prophylaxis | 13 | 2024 | 137 | 6.640 |
Why?
|
| Emergency Service, Hospital | 10 | 2024 | 484 | 3.100 |
Why?
|
| Sexual and Gender Minorities | 6 | 2023 | 192 | 2.290 |
Why?
|
| Electronic Health Records | 5 | 2023 | 320 | 1.930 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 301 | 1.660 |
Why?
|
| Betacoronavirus | 4 | 2020 | 258 | 1.480 |
Why?
|
| Medical Informatics | 2 | 2021 | 47 | 1.430 |
Why?
|
| Clostridium Infections | 2 | 2023 | 125 | 1.400 |
Why?
|
| Telemedicine | 2 | 2022 | 169 | 1.390 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 298 | 1.380 |
Why?
|
| Ambulatory Care Facilities | 5 | 2023 | 103 | 1.370 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 57 | 1.330 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 316 | 1.280 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 91 | 1.190 |
Why?
|
| Humans | 69 | 2024 | 86678 | 1.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 508 | 1.150 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 53 | 1.060 |
Why?
|
| Chicago | 13 | 2023 | 1380 | 1.050 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 39 | 1.040 |
Why?
|
| Pandemics | 11 | 2022 | 740 | 1.030 |
Why?
|
| AIDS Serodiagnosis | 3 | 2022 | 25 | 0.970 |
Why?
|
| Female | 38 | 2024 | 44550 | 0.960 |
Why?
|
| Adult | 29 | 2023 | 25659 | 0.950 |
Why?
|
| Contact Tracing | 2 | 2021 | 29 | 0.940 |
Why?
|
| Natural Language Processing | 2 | 2021 | 37 | 0.940 |
Why?
|
| Risk Assessment | 3 | 2020 | 2264 | 0.910 |
Why?
|
| Influenza, Human | 2 | 2016 | 329 | 0.880 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 78 | 0.880 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 30 | 0.880 |
Why?
|
| Sexual Partners | 2 | 2020 | 93 | 0.860 |
Why?
|
| Antimicrobial Stewardship | 2 | 2021 | 21 | 0.840 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 380 | 0.820 |
Why?
|
| Male | 33 | 2024 | 40988 | 0.800 |
Why?
|
| Hepatitis C | 1 | 2023 | 210 | 0.760 |
Why?
|
| Hospitalization | 5 | 2022 | 851 | 0.760 |
Why?
|
| Virus Shedding | 1 | 2020 | 26 | 0.750 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 9 | 0.740 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 103 | 0.740 |
Why?
|
| Ambulatory Care | 2 | 2023 | 181 | 0.730 |
Why?
|
| Middle Aged | 25 | 2021 | 25040 | 0.710 |
Why?
|
| Respiratory System | 1 | 2020 | 116 | 0.710 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.700 |
Why?
|
| HIV-1 | 1 | 2020 | 163 | 0.700 |
Why?
|
| Patient Compliance | 1 | 2021 | 228 | 0.690 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.690 |
Why?
|
| RNA, Viral | 1 | 2020 | 329 | 0.680 |
Why?
|
| Retrospective Studies | 19 | 2023 | 8496 | 0.670 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 12 | 0.670 |
Why?
|
| Heterosexuality | 1 | 2018 | 17 | 0.660 |
Why?
|
| Travel | 1 | 2018 | 68 | 0.640 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 73 | 0.630 |
Why?
|
| Referral and Consultation | 1 | 2020 | 328 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 747 | 0.620 |
Why?
|
| Antifungal Agents | 3 | 2017 | 117 | 0.610 |
Why?
|
| Cross Infection | 2 | 2016 | 141 | 0.610 |
Why?
|
| Coinfection | 4 | 2021 | 58 | 0.610 |
Why?
|
| United States | 11 | 2023 | 6681 | 0.590 |
Why?
|
| Itraconazole | 1 | 2016 | 11 | 0.580 |
Why?
|
| Residence Characteristics | 1 | 2018 | 197 | 0.580 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.570 |
Why?
|
| Violence | 1 | 2018 | 143 | 0.570 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 38 | 0.560 |
Why?
|
| Sorbitol | 1 | 2016 | 6 | 0.560 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 8 | 0.560 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 69 | 0.550 |
Why?
|
| Automation | 1 | 2016 | 106 | 0.540 |
Why?
|
| Population Surveillance | 1 | 2016 | 219 | 0.530 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 154 | 0.520 |
Why?
|
| Viral Load | 3 | 2020 | 150 | 0.510 |
Why?
|
| Continuity of Patient Care | 3 | 2022 | 169 | 0.500 |
Why?
|
| Machine Learning | 3 | 2022 | 232 | 0.500 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 35 | 0.500 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 23 | 0.500 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 146 | 0.490 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 44 | 0.490 |
Why?
|
| Hospitals | 1 | 2016 | 294 | 0.480 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 142 | 0.480 |
Why?
|
| Health Personnel | 1 | 2015 | 202 | 0.440 |
Why?
|
| Candida | 3 | 2017 | 17 | 0.430 |
Why?
|
| Logistic Models | 3 | 2022 | 1188 | 0.430 |
Why?
|
| Candidiasis | 3 | 2017 | 36 | 0.430 |
Why?
|
| Sepsis | 1 | 2016 | 306 | 0.420 |
Why?
|
| Algorithms | 4 | 2023 | 1830 | 0.410 |
Why?
|
| Risk Factors | 6 | 2023 | 5420 | 0.410 |
Why?
|
| Comorbidity | 4 | 2023 | 944 | 0.400 |
Why?
|
| Time Factors | 5 | 2022 | 5214 | 0.400 |
Why?
|
| Electronics | 2 | 2021 | 15 | 0.400 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 255 | 0.390 |
Why?
|
| Cities | 2 | 2021 | 40 | 0.380 |
Why?
|
| Vaccination | 2 | 2022 | 254 | 0.370 |
Why?
|
| Soft Tissue Infections | 2 | 2021 | 26 | 0.370 |
Why?
|
| Syphilis | 2 | 2021 | 27 | 0.360 |
Why?
|
| Inpatients | 3 | 2021 | 298 | 0.350 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 143 | 0.320 |
Why?
|
| Aged | 14 | 2021 | 18423 | 0.320 |
Why?
|
| Young Adult | 8 | 2021 | 5980 | 0.320 |
Why?
|
| Models, Theoretical | 2 | 2021 | 482 | 0.310 |
Why?
|
| Adolescent | 8 | 2021 | 8984 | 0.300 |
Why?
|
| Urban Population | 2 | 2018 | 214 | 0.300 |
Why?
|
| Medicare | 2 | 2020 | 410 | 0.270 |
Why?
|
| Survival Analysis | 2 | 2022 | 1538 | 0.270 |
Why?
|
| Mass Screening | 4 | 2022 | 619 | 0.250 |
Why?
|
| Community-Acquired Infections | 2 | 2021 | 63 | 0.240 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 66 | 0.230 |
Why?
|
| Qualitative Research | 1 | 2024 | 256 | 0.220 |
Why?
|
| Age Factors | 2 | 2018 | 1852 | 0.220 |
Why?
|
| Safe Sex | 2 | 2020 | 23 | 0.210 |
Why?
|
| Prospective Studies | 2 | 2021 | 4214 | 0.210 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2021 | 25 | 0.200 |
Why?
|
| HIV | 1 | 2021 | 46 | 0.200 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 54 | 0.200 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 12 | 0.200 |
Why?
|
| Minority Groups | 1 | 2022 | 137 | 0.200 |
Why?
|
| Demography | 1 | 2021 | 177 | 0.190 |
Why?
|
| Needle Sharing | 1 | 2020 | 14 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.190 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.190 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.190 |
Why?
|
| Postal Service | 1 | 2020 | 17 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Fungal | 2 | 2017 | 3 | 0.190 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.190 |
Why?
|
| Serologic Tests | 1 | 2020 | 41 | 0.190 |
Why?
|
| Critical Illness | 1 | 2023 | 294 | 0.180 |
Why?
|
| Social Networking | 1 | 2021 | 75 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 64 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 166 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 394 | 0.180 |
Why?
|
| Bias | 1 | 2020 | 127 | 0.180 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 8 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 865 | 0.170 |
Why?
|
| Illinois | 1 | 2020 | 462 | 0.170 |
Why?
|
| Condoms | 1 | 2019 | 36 | 0.170 |
Why?
|
| Geographic Information Systems | 1 | 2018 | 20 | 0.170 |
Why?
|
| Geographic Mapping | 1 | 2018 | 12 | 0.170 |
Why?
|
| Crime | 1 | 2018 | 36 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2018 | 173 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 879 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2020 | 350 | 0.160 |
Why?
|
| Risk-Taking | 1 | 2019 | 148 | 0.150 |
Why?
|
| Perception | 1 | 2018 | 168 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2018 | 319 | 0.150 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 17 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1981 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 265 | 0.140 |
Why?
|
| Histoplasmosis | 1 | 2016 | 25 | 0.140 |
Why?
|
| Symptom Assessment | 1 | 2016 | 65 | 0.140 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.140 |
Why?
|
| Penicillins | 1 | 2016 | 20 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 37 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1807 | 0.140 |
Why?
|
| Medicaid | 1 | 2018 | 217 | 0.130 |
Why?
|
| Seasons | 1 | 2016 | 223 | 0.130 |
Why?
|
| Sexual Behavior | 1 | 2018 | 302 | 0.130 |
Why?
|
| Nasopharynx | 1 | 2015 | 47 | 0.130 |
Why?
|
| Bacteriuria | 1 | 2014 | 10 | 0.130 |
Why?
|
| Pneumonia | 1 | 2016 | 179 | 0.120 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 71 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2016 | 239 | 0.120 |
Why?
|
| Infant | 2 | 2019 | 3047 | 0.120 |
Why?
|
| Obesity | 1 | 2020 | 964 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2019 | 3613 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1992 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 928 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6513 | 0.110 |
Why?
|
| Child | 3 | 2020 | 6928 | 0.110 |
Why?
|
| Trust | 2 | 2023 | 95 | 0.100 |
Why?
|
| Social Stigma | 2 | 2022 | 52 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 861 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 860 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2014 | 374 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1802 | 0.100 |
Why?
|
| Bacteria | 1 | 2014 | 447 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 160 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 2 | 2019 | 55 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7998 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1999 | 166 | 0.080 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2017 | 13 | 0.070 |
Why?
|
| Prevalence | 2 | 2022 | 1239 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.070 |
Why?
|
| Global Health | 2 | 2017 | 193 | 0.070 |
Why?
|
| Urinary Tract Infections | 2 | 2014 | 76 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 30 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 28 | 0.050 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.050 |
Why?
|
| Outpatients | 1 | 2021 | 94 | 0.050 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 426 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 20 | 0.050 |
Why?
|
| Medical Overuse | 1 | 2020 | 36 | 0.050 |
Why?
|
| Patient Participation | 1 | 2022 | 216 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 164 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 567 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1999 | 54 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 1999 | 9 | 0.040 |
Why?
|
| Synovial Membrane | 1 | 1999 | 28 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 122 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2021 | 95 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 160 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 674 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 263 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 680 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 840 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1999 | 3362 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 24 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2016 | 130 | 0.040 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 60 | 0.040 |
Why?
|
| DNA, Fungal | 1 | 2016 | 57 | 0.040 |
Why?
|
| Autopsy | 1 | 2016 | 116 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 89 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1994 | 25 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 52 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 29 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1578 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1037 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1994 | 132 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2379 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1994 | 435 | 0.030 |
Why?
|
| Prognosis | 2 | 2017 | 3680 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 72 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 141 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Contrast Media | 1 | 1994 | 1078 | 0.020 |
Why?
|
| Gadolinium DTPA | 2 | 1999 | 261 | 0.020 |
Why?
|
| Bone Cysts | 1 | 1999 | 10 | 0.010 |
Why?
|
| Synovitis | 1 | 1999 | 14 | 0.010 |
Why?
|
| Finger Joint | 1 | 1999 | 14 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 813 | 0.010 |
Why?
|
| Laminectomy | 1 | 1994 | 27 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1994 | 148 | 0.010 |
Why?
|